OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze

The episode begins with a light discussion on favorite podcasts and games, then delves into OpenAI's advancements and challenges in product development and energy use. It covers Google's Gemini in the AI market and cybersecurity in AI models. The Musk vs. Altman trial and the impact of therapy on leadership are analyzed. Big tech earnings, capital market shifts, and AI's economic implications are explored. The episode examines AI's risks and benefits in software development, highlights Retatrutide clinical trial results, Friedberg's Supreme Court experience, and discusses decision-making and public trust in the Supreme Court before concluding with closing remarks.